Does Anthem Cover Lantus?

How Anthem Classifies Lantus on Its Formulary

Anthem Blue Cross Blue Shield operates dozens of plan designs across commercial, employer-sponsored, ACA Marketplace, Medicaid managed care, and Medicare Advantage lines. Each plan maintains its own drug formulary, a tiered list that determines how much a member pays out of pocket for a given medication. Lantus (insulin glargine U-100, manufactured by Sanofi) appears on the majority of these formularies, but its tier placement varies.

Tier Placement Across Plan Types

On most Anthem commercial and Marketplace plans, Lantus falls on Tier 3 (non-preferred brand). Tier 3 copays typically range from $40 to $100 per 30-day supply, though some high-deductible health plans (HDHPs) require members to meet the full deductible before any copay kicks in. Anthem Medicare Advantage Part D plans also list Lantus, and these plans must comply with the Inflation Reduction Act's $35 monthly insulin copay cap that took full effect in January 2025.

Why Biosimilars Are Changing the Picture

Since the FDA approved insulin glargine biosimilars, including Semglee (insulin glargine-yfgn) in 2020 and Rezvoglar (insulin glargine-aglr) in 2021, Anthem has increasingly placed these products on preferred brand (Tier 2) or even preferred generic tiers. A 2023 analysis in Diabetes Care found that biosimilar insulin glargine products were priced 40% to 65% below brand Lantus at wholesale acquisition cost [1]. For Anthem members, this tier shift can mean the difference between a $90 copay for brand Lantus and a $25 copay for a biosimilar equivalent.

Step Therapy Considerations

Some Anthem plans now impose step therapy (also called "fail first") protocols that require members to try a biosimilar insulin glargine before the plan will authorize brand-name Lantus at the lower tier copay. If your prescriber believes brand Lantus is medically necessary (for example, due to a documented adverse reaction to a biosimilar excipient), they can file a formulary exception request.

What Lantus Costs with Anthem Insurance

Out-of-pocket cost depends on three variables: your plan's tier structure, whether you have met your deductible, and whether federal or state insulin cost caps apply.

Copay and Coinsurance Ranges

Anthem's Tier 3 copays for a 30-day Lantus supply generally fall between $40 and $100 on PPO and HMO plans. Some plans use coinsurance instead of flat copays, meaning members pay a percentage (often 25% to 40%) of the drug's negotiated price. For a Lantus SoloStar 5-pen box with a negotiated plan price near $350, a 30% coinsurance would produce roughly $105 out of pocket before any manufacturer coupon or copay assistance. The American Diabetes Association's Standards of Care (2024) emphasizes that cost barriers to insulin are a primary driver of non-adherence and recommends clinicians actively assist patients in navigating formulary options [2].

The $35 Insulin Cap

The Inflation Reduction Act capped insulin copays at $35 per month for Medicare Part D enrollees starting in 2025 [3]. Many Anthem commercial plans have voluntarily adopted a similar cap. According to a 2024 CMS report, the $35 cap saved Medicare beneficiaries an average of $500 per year on insulin costs [4]. If you are on an Anthem Medicare Advantage plan, your Lantus copay will not exceed $35 per monthly supply regardless of the formulary tier.

Manufacturer Savings Programs

Sanofi operates the Insulins Valyou Savings Program, which caps the out-of-pocket cost of Lantus at $35 per 30-day prescription for commercially insured patients. This program can stack with insurance benefits in certain plan designs, though it does not apply to government-funded insurance (Medicare, Medicaid, TRICARE). Members should verify stacking eligibility with both Anthem and Sanofi before assuming a combined benefit.

Prior Authorization and Quantity Limits

For most Anthem plans, Lantus does not require prior authorization when prescribed for a standard Type 1 or Type 2 diabetes diagnosis. The prescriber writes the script, and the pharmacy processes it against the formulary tier.

When PA Is Required

Prior authorization may be triggered in specific circumstances: doses exceeding standard quantity limits (more than 10 mL of vial insulin or 5 KwikPen devices per 30 days), off-label use, or requests to override step therapy requiring a biosimilar trial first. Anthem's clinical pharmacy team reviews these requests, typically within 72 hours for standard requests and 24 hours for urgent or expedited reviews.

Filing an Exception

If Anthem denies coverage or places Lantus at a tier that creates financial hardship, members have the right to file a formulary exception. The ADA's position statement on insulin access notes: "Payers should provide transparent and timely processes for formulary exceptions when a prescribed insulin is not on the preferred list" [2]. Your prescriber must submit a letter of medical necessity explaining why the specific brand product is required over available alternatives.

Biosimilar Insulin Glargine Alternatives on Anthem

Biosimilar insulin glargine products offer the same active molecule, the same mechanism of action, and clinically equivalent glycemic control to brand Lantus. The FDA's biosimilar approval pathway requires manufacturers to demonstrate that their product has no clinically meaningful differences from the reference product in safety, purity, and potency [5].

Semglee (Insulin Glargine-yfgn)

Semglee, manufactured by Biocon/Viatris, was the first interchangeable biosimilar insulin approved by the FDA. "Interchangeable" status means a pharmacist can substitute Semglee for brand Lantus without prescriber intervention, similar to how generic drugs are dispensed. On many Anthem formularies, Semglee sits on Tier 2 with copays between $20 and $50. The INSTRIDE trials demonstrated equivalent HbA1c reduction between Semglee and reference Lantus, with a mean difference of 0.05% (95% CI: -0.12 to 0.22), well within the FDA's equivalence margin [6].

Rezvoglar (Insulin Glargine-aglr)

Rezvoglar, manufactured by Eli Lilly, received FDA approval as a biosimilar (not interchangeable) to Lantus. It requires a specific prescription. On Anthem plans that list it, Rezvoglar typically appears on Tier 2 or Tier 3 depending on the negotiated rebate. Its wholesale acquisition cost runs approximately 40% below brand Lantus [1].

Toujeo (Insulin Glargine U-300)

Toujeo is not a biosimilar but a concentrated formulation (300 units/mL vs. Lantus's 100 units/mL) also manufactured by Sanofi. Anthem plans may cover Toujeo for patients requiring high daily basal insulin doses (typically above 60 units per day), as the EDITION clinical trial program showed Toujeo produced comparable HbA1c lowering with 14% fewer nocturnal hypoglycemic events compared to Lantus in Type 2 diabetes [7]. Toujeo usually sits on Tier 3 and may require prior authorization.

How to Verify Your Specific Anthem Plan's Coverage

No two Anthem plans are identical. The details above reflect common patterns, not guarantees for your individual plan.

Check the Online Formulary Tool

Log in to anthem.com, manage to "Find a Drug" or "Pharmacy," and search for "insulin glargine" or "Lantus." The tool will display the tier, any PA or step therapy requirements, and quantity limits specific to your plan ID. Dr. Irl Hirsch, professor of medicine at the University of Washington and a specialist in diabetes management, has noted: "Patients should verify their specific formulary at least once per plan year, because insurers reclassify drugs more frequently than most people realize" [8].

Call Member Services

The number on the back of your Anthem ID card connects you to a benefits representative who can confirm real-time coverage status, current copay amounts, and whether any utilization management criteria apply. Ask specifically: "What tier is Lantus on my plan?" and "Are there biosimilar alternatives at a lower tier?"

Ask Your Pharmacist

Pharmacists can run a real-time benefits check (RTBC) at the point of sale, which queries Anthem's adjudication system and returns the exact copay or coinsurance for Lantus and any available alternatives. This tool also flags whether a biosimilar substitution would lower the cost. A 2022 study in the Journal of the American Pharmacists Association found that RTBC use reduced patient out-of-pocket insulin spending by an average of 23% when pharmacists actively recommended lower-cost alternatives [9].

Tips to Lower Your Lantus Cost with Anthem

Even with insurance, basal insulin costs add up over 12 months. Several strategies can reduce annual spending.

Switch to a Preferred Biosimilar

If your Anthem plan places Semglee or Rezvoglar on a lower tier, ask your prescriber to write for the biosimilar. The clinical equivalence data is strong. Switching from brand Lantus to an interchangeable biosimilar requires no dose adjustment and no additional monitoring beyond what you already do [5].

Use Anthem's Preferred Pharmacy Network

Anthem plans often offer lower copays at preferred or mail-order pharmacies. A 90-day mail-order supply can reduce per-unit costs by 10% to 20% compared to 30-day retail fills. Check your plan's pharmacy directory for preferred retail chains and the mail-order option.

Apply Manufacturer Copay Cards

Sanofi's Valyou Savings Program and similar copay assistance programs can reduce out-of-pocket costs to $35 or less for commercially insured members. Biocon/Viatris also offers savings programs for Semglee. These cards are presented at the pharmacy alongside your insurance card.

Request a Formulary Exception for Financial Hardship

If you face documented financial hardship and a biosimilar is not appropriate for your clinical situation, Anthem must consider a tier exception request. Approval moves the drug to a lower cost-sharing tier for the remainder of the plan year.

Explore Patient Assistance Programs

For members in the coverage gap ("donut hole") on Medicare Part D or those with very high coinsurance, Sanofi's Patient Connection program provides free Lantus to qualifying individuals with household incomes below 400% of the federal poverty level. The FDA's resource page on patient assistance programs lists additional options [10].

Anthem Coverage for Lantus Supplies and Accessories

Insulin coverage extends beyond the drug itself. Blood glucose monitors, test strips, lancets, pen needles, and continuous glucose monitors (CGMs) are covered under separate benefit categories on Anthem plans.

Pen Needles and Syringes

Most Anthem plans cover pen needles and syringes as pharmacy benefits (processed at the pharmacy counter). Standard quantity limits allow 100 pen needles or syringes per 30 days. There is no prior authorization for standard quantities.

Continuous Glucose Monitors

CGMs such as the Dexcom G7 and FreeStyle Libre 3 are increasingly covered by Anthem, particularly for members on basal-bolus insulin regimens. The ADA Standards of Care recommend CGM for all adults with Type 1 diabetes and adults with Type 2 diabetes on intensive insulin therapy [2]. Coverage may require prior authorization documenting the insulin regimen and frequency of blood glucose testing.

What Happens If Anthem Denies Lantus Coverage

Denial is uncommon for standard diabetes indications but does occur, most often due to step therapy requirements or quantity limit overages.

Internal Appeal

You have 180 days from the denial date to file an internal appeal. Include your prescriber's letter of medical necessity, relevant lab results (HbA1c, fasting glucose), and documentation of any adverse reactions to alternative insulins. Anthem must respond within 30 days for standard appeals, 72 hours for expedited appeals.

External Review

If the internal appeal is denied, you can request an independent external review through your state's insurance department. The external reviewer's decision is binding on Anthem. The Endocrine Society's clinical practice guideline on insulin therapy can provide supporting evidence for your prescriber's medical necessity argument [11].